Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$47.98 - $54.4 $14,489 - $16,428
-302 Reduced 4.42%
6,529 $354,000
Q4 2023

Jan 29, 2024

BUY
$48.48 - $57.85 $37,717 - $45,007
778 Added 12.85%
6,831 $350,000
Q3 2023

Oct 23, 2023

SELL
$57.89 - $64.73 $11,578 - $12,946
-200 Reduced 3.2%
6,053 $351,000
Q1 2023

May 08, 2023

BUY
$65.71 - $74.53 $16,558 - $18,781
252 Added 4.2%
6,253 $433,000
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $109,568 - $129,744
-1,600 Reduced 21.05%
6,001 $431,000
Q3 2022

Oct 25, 2022

SELL
$0.13 - $76.84 $39 - $23,128
-301 Reduced 3.81%
7,601 $540,000
Q2 2022

Jul 27, 2022

SELL
$72.62 - $79.98 $2.89 Million - $3.18 Million
-39,728 Reduced 83.41%
7,902 $608,000
Q1 2022

Apr 21, 2022

BUY
$61.48 - $73.72 $87,977 - $105,493
1,431 Added 3.1%
47,630 $3.48 Million
Q4 2021

Feb 08, 2022

BUY
$53.63 - $62.52 $500,153 - $583,061
9,326 Added 25.29%
46,199 $2.88 Million
Q3 2021

Oct 29, 2021

BUY
$59.17 - $69.31 $164,196 - $192,335
2,775 Added 8.14%
36,873 $2.18 Million
Q2 2021

Aug 02, 2021

BUY
$61.91 - $67.42 $375,422 - $408,834
6,064 Added 21.63%
34,098 $2.28 Million
Q1 2021

May 11, 2021

BUY
$59.34 - $66.74 $426,001 - $479,126
7,179 Added 34.42%
28,034 $1.77 Million
Q4 2020

Jan 26, 2021

BUY
$57.74 - $65.43 $456,261 - $517,027
7,902 Added 61.01%
20,855 $1.29 Million
Q3 2020

Nov 09, 2020

BUY
$57.43 - $63.64 $45,025 - $49,893
784 Added 6.44%
12,953 $781,000
Q2 2020

Aug 03, 2020

BUY
$54.82 - $64.09 $271,687 - $317,630
4,956 Added 68.71%
12,169 $716,000
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $141,056 - $204,987
3,040 Added 72.85%
7,213 $402,000
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $205,353 - $267,864
4,173 New
4,173 $268,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Live Oak Private Wealth LLC Portfolio

Follow Live Oak Private Wealth LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Live Oak Private Wealth LLC, based on Form 13F filings with the SEC.

News

Stay updated on Live Oak Private Wealth LLC with notifications on news.